Michael K Schultz
Overview
Explore the profile of Michael K Schultz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
57
Citations
707
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Saini S, Bartels J, Appiah J, Rider J, Baumhover N, Schultz M, et al.
J Nucl Med
. 2023 Aug;
64(11):1791-1797.
PMID: 37652545
Pb is a surrogate imaging match for Pb. This elementally matched pair is emerging as a suitable pair for imaging and targeted radionuclide therapy in cancer care. Because of the...
12.
Li M, Baumhover N, Liu D, Cagle B, Boschetti F, Paulin G, et al.
Pharmaceutics
. 2023 Feb;
15(2).
PMID: 36839736
Pb and Pb have emerged as promising theranostic isotopes for image-guided α-particle radionuclide therapy for cancers. Here, we report a cyclen-based Pb specific chelator (PSC) that is conjugated to tyr-octreotide...
13.
Nelson B, Wilson J, Schultz M, Andersson J, Wuest F
Nucl Med Biol
. 2023 Jan;
116-117:108314.
PMID: 36708660
Introduction: Pb (t = 51.9 h, 279 keV (81 %)) is a diagnostic SPECT imaging radionuclide ideally suited for theranostic applications in combination with Pb for targeted alpha particle therapy....
14.
Muller D, Herrmann H, Schultz M, Solbach C, Ettrich T, Prasad V
Clin Nucl Med
. 2022 Oct;
48(1):54-55.
PMID: 36257061
In an end-stage midgut neuroendocrine tumor patient with carcinoid heart disease, right ventricular dysfunction, mildly reduced renal function, and refractory to 6 cycles of 177 Lu-HA-DOTATATE therapy, planar, and 22...
15.
Orcutt K, Henry K, Habjan C, Palmer K, Heimann J, Cupido J, et al.
Molecules
. 2022 Sep;
27(18).
PMID: 36144563
[Pb]VMT01 is a melanocortin 1 receptor (MC1R) targeted theranostic ligand in clinical development for alpha particle therapy for melanoma. Pb has an elementally matched gamma-emitting isotope Pb; thus, [Pb]VMT01 can...
16.
Li M, Liu D, Lee D, Cheng Y, Baumhover N, Marks B, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359580
Radiotherapy can facilitate the immune recognition of immunologically "cold" tumors and enhance the efficacy of anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitors (ICIs) in melanoma. Systemic administration of receptor-targeted radionuclide therapy...
17.
Varmazyad M, Modi M, Kalen A, Sarsour E, Wagner B, Du J, et al.
Free Radic Biol Med
. 2021 Feb;
165:421-434.
PMID: 33561488
Dihydroartemisinin (DHA) is an FDA-approved antimalarial drug that has been repurposed for cancer therapy because of its preferential antiproliferative effects on cancer versus normal cells. Mitochondria represent an attractive target...
18.
Kloepping K, Kraus A, Hedlund D, Gnade C, Wagner B, McCormick M, et al.
PLoS One
. 2020 Dec;
15(12):e0244540.
PMID: 33378390
Despite dramatic improvements in outcomes arising from the introduction of targeted therapies and immunotherapies, metastatic melanoma is a highly resistant form of cancer with 5 year survival rates of <35%....
19.
Kunos C, Mankoff D, Schultz M, Graves S, Pryma D
Semin Radiat Oncol
. 2020 Nov;
31(1):3-11.
PMID: 33246634
Radiation oncologists and nuclear medicine physicians have seen a resurgence in the clinical use of radiopharmaceuticals for the curative or palliative treatment of cancer. To enable the discovery and the...
20.
Li M, Sagastume E, Lee D, McAlister D, DeGraffenreid A, Olewine K, et al.
Curr Med Chem
. 2020 Jul;
27(41):7003-7031.
PMID: 32720598
Receptor-targeted image-guided Radionuclide Therapy (TRT) is increasingly recognized as a promising approach to cancer treatment. In particular, the potential for clinical translation of receptor-targeted alpha-particle therapy is receiving considerable attention...